By Topic

Analysis of mass spectrometry data for serum biomarker discovery

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$33 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

9 Author(s)
Habtom W. Ressom ; Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC, USA ; Rency S Varghese ; Lenka Goldman ; Christopher A. Loffredo
more authors

We present a computational framework to analyze MALDI-TOF mass spectrometry data for quantitative comparison of peptides and glycans in serum. In particular, we introduce an algorithm that detects peaks that are differentially abundant in a subgroup of patients. The method is applied to identify candidate biomarkers in serum samples of 203 participants from Egypt; 73 hepatocellular carcinoma (HCC) cases, 52 patients with chronic liver disease (CLD), and 78 healthy individuals. Mass spectra were generated using two experiments: (1) low molecular weight (LMW) enriched serum samples were used for MALDI-TOF quantification of peptides, and (2) glycans were enzymatically released from proteins in serum and permethylated prior to MALDI-TOF quantification. A subset of the participants (35 HCC and 35 CLD cases) was used to select the most useful peaks. The peak selection step is preceded by peak screening, where we eliminated peaks that seem to have association with covariates such as age, gender, and viral infection based on the 78 spectra from healthy individuals. The performance of the selected peaks was evaluated in terms of detecting the disease state of a blinded independent set that comprised of 38 HCC and 17 CLD cases. Further evaluation of the potential clinical utility of the selected candidate peptide and glycan markers is needed.

Published in:

Life Science Systems and Applications Workshop, 2007. LISA 2007. IEEE/NIH

Date of Conference:

8-9 Nov. 2007